Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending February 8, 2017. The document serves as a transaction notification regarding insider trading activities involving Persons Discharging Managerial Responsibilities (PDMRs) and persons closely associated with them.
Key Financial Metrics
The filing does not contain corporate financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. It exclusively reports on specific share transactions.
| Transaction Date | Instrument | Price per ADS | Volume | Transaction Type |
|---|---|---|---|---|
| February 7, 2017 | GSK American Depositary Shares (ADSs) | $39.46 | 29 ADSs | Notional Allocation (401K Plan) |
| February 7, 2017 | GSK American Depositary Shares (ADSs) | $39.46 | 11 ADSs | Notional Allocation (401K Plan) |
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document details two separate increases in ADS holdings resulting from the revaluation of cash elements within the GSK 401(K) plan.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It is a statutory disclosure of specific share movements.
Key Facts for Investor Verification
- Transaction Nature: The reported increases in shareholdings were not open market purchases but resulted from notional allocations within the GSK 401(K) plan.
- Individuals Involved: The transactions involved Dr. M M Slaoui (Chairman, Global Vaccines) and Dr. K Slaoui (Person Closely Associated with Dr. M M Slaoui).
- Valuation: Both transactions occurred at a price of $39.46 per ADS on February 7, 2017.
- Scope: This filing does not provide any data on GSK's overall financial health or operational results for the period.